On October 26thth In 2022, CRISPR QC announced that Toby Richardson, PhD, had been appointed to the Board of Directors.
CRISPR QC has already begun proving that the unique capabilities of our CRISPR Analytics platform can query unprecedented dimensions of gene editing, which translates into real value for our customers,” said Ross Bundy, CEO. “The next step in our evolution is to gain unique insights and build greater depth of our data and analytics capabilities. The extensive experience of Dr. Richardson in this space will be key to driving this emerging aspect of our business.”
“I am honored to join the CRISPR QC Board of Directors. CRISPR QC’s CRISPR analytics platform is unique and offers many new types of data-driven insights that will greatly benefit therapeutics, biotech and agtech companies. I look forward to contributing to QC’s CRISPR data strategy to realize its full potential,” says Toby Richardson, PhD.
dr Richardson co-founded Denovium Inc. in 2018, a company that used cutting-edge deep learning technology to solve the big data problems facing the pharmaceutical and industrial biotech industries. Toby brings over two decades of industrial experience leading bioinformatics teams and developing and commercializing genomics software. Toby has served on the board of directors of Agracast and as a scientific advisor to several biotech companies. He is the author of more than 30 peer-reviewed publications and inventor of more than 20 patents. dr Richardson holds a PhD in Drug Metabolism from the University of Surrey.
CRISPR has the potential to become the defining technology of the 21st centurySt Century. CRISPR promises to cure previously incurable diseases, secure our food supply and much more. However, these advances are not without risks or blind spots. The need for quality control and insights has grown in tandem with the advances and successes of CRISPR gene editing. At CRISPR QC, we leverage our CRISPR Analytics Platform, powered…
